8 recruiting, 6 unknown, 4 completed, 4 terminated. 12 Phase 2, 7 Phase 1, 5 Phase 3, 4 Not applicable.
Follow Acute Myeloid Leukemia, Adult: new trials by email Literature Review of Acute Myeloid Leukemia, Adult trials Research Report on Acute Myeloid Leukemia, Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice Bone marrow or peripheral blood withdrawal for test comparison - Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult | Not applicable | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 75 | 2027-01-01 | 2026-10-09 |
| NAC for Hematopoietic Recovery in Low/Intermediate-Risk AML After CR: A Randomized Controlled Study N-acetyl-L-cysteine (NAC) - Acute Myeloid Leukemia, Adult | Not applicable | Not yet recruiting | Peking University People's Hospital | 180 | 2026-10-01 | 2026-10-09 |
| Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) Azacitidine, Venetoclax, Quizartinib - Acute Myeloid Leukemia, Adult | Phase 3 | Recruiting | PETHEMA Foundation | 376 | 2026-07-02 | 2026-10-07 |
| Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) Acute Myeloid Leukemia, AML, Adult | Recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 397 | 2025-07-11 | 2025-08-13 | |
| Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML Revumenib, Placebo - Acute Myeloid Leukemia, Adult | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 448 | 2025-05-05 | 2026-09-02 |
| Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia VACl, VACh, VACl Alternating With VACh - Acute Myeloid Leukemia, Adult, Newly Diagnosed | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 172 | 2024-07-29 | 2025-11-19 |
| A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients Hydroxyurea, Hydroxycarbamide, Valproic acid, 6-Mercaptopurine (6-MP) - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult | Phase 1 / Phase 2 | Recruiting | Haukeland University Hospital | 48 | 2024-05-23 | 2025-06-29 |
| Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients Vaccines, Peptide - Acute Myeloid Leukemia, Adult | Phase 1 | Not yet recruiting | University Hospital Tuebingen | 20 | 2024-05-02 | 2024-02-09 |
| Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult DEC3-VEN - Acute Myeloid Leukemia, Adult | Phase 2 / Phase 3 | Unknown | The Second Affiliated Hospital of Kunming Medical University | 40 | 2024-03-01 | 2024-02-29 |
| Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease Acute Myeloid Leukemia, Adult, Graft Versus Host Disease | Withdrawn | Ugur Arzu Kulu | 2023-11-15 | 2025-01-29 | ||
| Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy Selinexor, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Adult | Phase 1 / Phase 2 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 6 | 2023-05-05 | 2025-05-30 |
| Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome Fludarabine and Busulfan, Fludarabine and Melphalan - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS) | Phase 3 | Enrolling by invitation | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 200 | 2023-02-15 | 2025-02-10 |
| Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML History taking, Anthropometry, Complete blood count - Acute Myeloid Leukemia, Adult, Cardiotoxicity | Not applicable | Completed | Samara State Medical University | 100 | 2022-12-01 | 2026-10-16 |
| First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients ABD-3001 - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Advanced BioDesign | 36 | 2022-11-08 | 2025-01-20 |
| A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML Clifutinib Besylate - Acute Myeloid Leukemia, Adult | Phase 1 / Phase 2 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 133 | 2022-10-31 | 2026-05-15 |
| Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia cladribine + homoharringtonine + cytarabine - Acute Myeloid Leukemia, Adult | Phase 2 | Completed | First Affiliated Hospital of Zhejiang University | 65 | 2022-10-26 | 2026-02-04 |
| Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia ADI-PEG 20 - Acute Myeloid Leukemia, Adult | Phase 1 | Active not recruiting | Polaris Group | 38 | 2022-04-05 | 2026-10-15 |
| RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old. Evaluation of first line treatment with intensive treatment outcome in adult patients with AML. - Acute Myeloid Leukemia, Adult | Unknown | Grupo Argentino de Tratamiento de la Leucemia Aguda | 50 | 2021-03-01 | 2021-11-19 | |
| Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features venetoclax combined with decitabine - Acute Myeloid Leukemia, Adult | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 42 | 2021-02-20 | 2021-11-15 |
| Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay Experimental group, Control group - Acute Myeloid Leukemia, Adult | Not applicable | Unknown | Hospital General de Mexico | 74 | 2020-12-01 | 2020-09-03 |
Showing 20 of 28. Sign in to see all of them.
Leukemia, Myeloid, Acute (28) · Myelodysplastic Syndromes (3) · Recurrence (2) · Cardiotoxicity (1) · Graft vs Host Disease (1) · Leukemia (1) · Leukemia, Promyelocytic, Acute (1)
Hematologic Diseases (28) · Hemic and Lymphatic Diseases (28) · Leukemia, Myeloid (28) · Neoplasms (28) · Neoplasms by Histologic Type (28) · Leukemia (27) · Bone Marrow Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Disease Attributes (2) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Drug-Related Side Effects and Adverse Reactions (1) · Heart Diseases (1) · Immune System Diseases (1)
Azacitidine (4) · venetoclax (4) · Cytarabine (3) · Decitabine (3) · fludarabine (3) · Cladribine (2) · fludarabine phosphate (2) · ADI PEG20 (1) · Acetylcysteine (1) · Anthropometry (1) · Blood Cell Count (1) · Busulfan (1) · CPX-351 (1) · Control Groups (1) · Cyclophosphamide (1)
Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · The First Affiliated Hospital of Soochow University (2) · Advanced BioDesign (1) · Chunyan Ji (1) · First Affiliated Hospital of Zhejiang University (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Grupo Argentino de Tratamiento de la Leucemia Aguda (1) · Haukeland University Hospital (1) · Hospital General de Mexico (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Ospedale Maggiore Di Trieste (1) · PETHEMA Foundation (1) · Peking University People's Hospital (1) · Polaris Group (1) · Samara State Medical University (1)
China (7) · United States (5) · Italy (4) · Germany (3) · France (2) · Norway (2) · Spain (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Denmark (1) · Estonia (1) · Finland (1) · Ireland (1)
Andrea Bacigalupo, Prof. (1) · Anna Candoni (1) · Chunyan Ji, Doctor (1) · Claudia Sossa (1) · Francesco Zaja, Professor (1) · Gerwin Huls, MD (1) · Hernan Dick, Dr. (1) · Igor Davydkin (1) · Isolda Fernandez, Dr. (1) · Jie Jin, Doctor (1) · Jie Sun (1) · Joana Brioso (1) · John S Bomalaski, MD (1) · Juan Bergua (1)
PMID 20668231, PMID 27895058, PMID 39333315, PMID 39392121, PMID 41043134
2019 (1)